Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Long-Term Investments of $54.0 million for Q1 2026, up 575.0% year-over-year from $8.0 million in Q1 2025, and up 86.21% quarter-over-quarter from $29.0 million in Q4 2025.
Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2026) Analysis & Trends
Arcus Biosciences' Long-Term Investments history runs 10 years deep, the most recent figure standing at $54.0 million for Q1 2026.
- In Q1 2026, Long-Term Investments rose 575.0% year-over-year to $54.0 million; the TTM figure through Mar 2026 stood at $54.0 million (up 575.0% YoY), while the FY2025 annual figure was $29.0 million, up 107.14% from the prior year.
- Long-Term Investments for Q1 2026 stood at $54.0 million, up from $29.0 million in the prior quarter.
- The five-year high for Long-Term Investments was $151.0 million in Q3 2023, with the low at $2.0 million in Q3 2024.
- The 5-year median for Long-Term Investments is $80.0 million (2023), against an average of $70.6 million.
- The sharpest annual moves came in 2024 and 2026: Long-Term Investments slumped 98.68% in 2024, then soared 575.0% in 2026.
- Arcus Biosciences' Long-Term Investments stood at $129.0 million in 2022, then retreated by 17.05% to $107.0 million in 2023, then tumbled by 86.92% to $14.0 million in 2024, then jumped by 107.14% to $29.0 million in 2025, then jumped by 86.21% to $54.0 million in 2026.
- Business Quant data shows RCUS's Long-Term Investments at $54.0 million in Q1 2026, $29.0 million in Q4 2025, and $10.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 73.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.00 Mn |
| Mar 31, 2026 | 54.00 Mn |
| Dec 31, 2025 | 29.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 16.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 14.00 Mn |
| Sep 30, 2024 | 2.00 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Mar 31, 2024 | 100.00 Mn |
| Dec 31, 2023 | 107.00 Mn |
| Sep 30, 2023 | 151.00 Mn |
| Jun 30, 2023 | 80.00 Mn |
| Mar 31, 2023 | 90.00 Mn |
| Dec 31, 2022 | 129.00 Mn |
| Sep 30, 2022 | 143.14 Mn |
| Jun 30, 2022 | 98.33 Mn |
| Mar 31, 2022 | 128.84 Mn |
| Dec 31, 2021 | 182.00 Mn |
| Sep 30, 2021 | 218.73 Mn |